Online first
Short communication
Published online: 2025-01-15

open access

Page views 179
Article views/downloads 92
Get Citation

Connect on Social Media

Connect on Social Media

Angiogenic markers as prognostic tools in patients with COVID-19: CRACoV-HHS study

Katarzyna Stolarz-Skrzypek1, Agnieszka Olszanecka1, Wiktoria Wojciechowska1, Michał Terlecki12, Piotr Kusak3, Agnieszka Bednarek3, Jakub Rusinek4, Beata Kuśnierz-Cabala5, Maria Kapusta6, Barbara Wizner7, Marcin Krzanowski8, Andrzej Surdacki9, Katarzyna Krzanowska8, Marek Sanak10, Maciej Małecki11, Tomasz Grodzicki7, Marek Rajzer1

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Covid- L. COVID-19 Epidemiological Update Key highlights 2025.
  2. Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: Current evidence and perspectives. High Blood Press Cardiovasc Prev. 2022; 29(2): 115–123.
  3. Pająk A, Jankowski P, Zdrojewski T. The burden of cardiovascular disease risk factors: A current problem. Kardiol Pol. 2022; 80(1): 5–15.
  4. Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: The angiogenic-placental syndrome. Hypertension. 2020; 75(4): 918–926.
  5. Wojciechowska E, Cienszkowska K, Ludwiczak M, et al. Uncontrolled blood pressure according to ambulatory blood pressure monitoring values in pregnant women is poorly predictable. Kardiol Pol. 2023; 81(7-8): 763–765.
  6. Nägele MP, Haubner B, Tanner FC, et al. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020; 314: 58–62.
  7. National Institutes of Health. Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). Nih [Internet]. 2021; 2019: 1–243. . https://www.covid19treatmentguidelines.nih.gov/.%0Ahttps://www.covid19treatmentguidelines.nih.gov/ (accessed: November 5, 2024).
  8. Sydor W, Wizner B, Strach M, et al. CRACoV-HHS: An interdisciplinary project for multi-specialist hospital and non-hospital care for patients with SARS-CoV-2 infection as well hospital staff assessment for infection exposure. Folia Med Cracov. 2021; 61(4): 5–44.
  9. Zhang JJ, Dong X, Liu GH, et al. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023; 64(1): 90–107.
  10. Terlecki M, Wojciechowska W, Klocek M, et al. Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland. Kardiol Pol. 2021; 79(7-8): 773–780.
  11. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020; 383(2): 120–128.
  12. Pine AB, Meizlish ML, Goshua G, et al. Circulating markers of angiogenesis and endotheliopathy in COVID-19. medRxiv. 2020.
  13. Mohebbi A, Haybar H, Nakhaei Moghaddam F, et al. Biomarkers of endothelial dysfunction are associated with poor outcome in COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol. 2023; 33(4): e2442.
  14. Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020; 23(4): 611–620.
  15. Madureira G, Soares R. The misunderstood link between SARS-CoV-2 and angiogenesis. A narrative review. Pulmonology. 2023; 29(4): 323–331.